Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.

Abstract: In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The medicant moiety can be a toxin including an acylfulvene or a drug moiety. The affinity moiety can be an antibody, a binding protein, a steroid, a lipid, a growth factor, a protein, a peptide or non peptidic. The affinity moiety can be covalently bound to the medicant via a linker. Novel linkers that can be directed to cysteine, arginine or lysine residues based on solution pH allow greater flexibility in preserving and/or generating specific epitopes in the AMC.

Abstract: The present disclosure is directed to methods of treating patients with chronic kidney disease (CKD), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin.

Abstract: A method of preparing polylactic acid (PLA) microsphere and polylactic-co-glycolic acid (PLGA) microsphere is provided, including the following steps. A first solution is provided, including polylactic acid or polylactic-co-glycolic acid and an organic solvent. A second solution is provided, including polyvinyl alcohol, sodium carboxymethyl cellulose and an aqueous solution. The first solution is added to the second solution and, at the same time, the second solution is agitated until polylactic acid is solidified to form a plurality of polylactic acid microspheres, or until polylactic-co-glycolic acid is solidified to form a plurality of polylactic-co-glycolic acid microspheres. The polylactic acid microspheres or polylactic-co-glycolic acid microspheres are collected.

Abstract: The present invention relates to methods for treating or preventing chronic kidney disease and cardiovascular disease in patients with chronic kidney disease comprising administering empagliflozin to the patient.

Abstract: Provided herein are methods of producing an adeno-associated virus (AAV) product, methods of purifying adeno-associated virus, and methods of purifying full AAV capsids from a concentrated AAV fraction comprising empty AAV capsids and full AAV capsids.

Abstract: Composition for use in the prevention and/or treatment of a liver disease in a mammal, the composition comprising an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine and the carboxylic acids citric acid, succinic acid, malic acid.

Abstract: The invention discloses herein related to synergistic combination of exogenous bioactives for activating intracellular secondary messenger (cAMP) signalling pathway. Particularly, the invention relates to synergistic compositions comprising combination of therapeutically effective amount of (3R)-3-acetyloxy-4-(trimethylazaniumyl) butanoate and N-4-aminobutylguanidine and salts thereof present in a weight ratio of 1:0.01 to 1:2 along with pharmaceutically acceptable excipients. Furthermore, the composition is useful for treating disease conditions or disorders related to depletion of secondary messenger pathway. The present invention further provides method of treating disease conditions related mental illness or disorder.

Abstract: The present disclosure is directed to methods of treating patients with chronic kidney disease (CKD), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin.

Abstract: The invention relates to a pharmaceutical composition in the form of a tablet, said tablet comprising a tablet core, wherein said core comprises benzgalantamine (ALPHA-1062) or salt thereof, and an enteric coating, wherein said enteric coating is configured for dissolution at pH 5.5 and above. Further the invention relates to the pharmaceutical composition for use in the treatment of a brain disease associated with cognitive impairment and/or with a cholinergic deficit. The invention further relates to a method for preparing the pharmaceutical composition.

Abstract: This invention provides a way for drugs to kill a wide variety of otherwise invulnerable arthropods, which are protected by an unwettable plastron shield that encoats their bodies, by providing the drug with a means of egress through this plastron. Also, many arthropod-related diseases are caused by a combination of underlying factors, not just the mite. This invention allows for the concomitant use of other, non-mite-related, lipophilic drugs. This “combo” drug approach potentially allows for the treatment of the all of factors causing the disease at the same time.

Abstract: A process for transglucosylation of steviol glycosides. A sweetener composition having at least 95% total glycosylated steviol glycosides.

Abstract: A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.

Abstract: The present invention concerns the compound aprocitentan, {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide: and its use as endothelin receptor antagonist, in combination with an SGLT-2 inhibitor. The invention further relates to pharmaceutical compositions comprising aprocitentan in combination with said SGLT-2 inhibitor. The invention further relates to such pharmaceutical compositions comprising crystalline forms of aprocitentan.

Abstract: The disclosure discloses a chemical synthesis method of oligosaccharides of a Pseudomonas aeruginosa serotype O11 O-antigen, and belongs to the field of chemistry. The disclosure includes constructing an O-antigen trisaccharide by using a D-glucose building block, an L-fucosamine building block and a D-fucosamine building block; wherein the D-glucose building block or the L-fucosamine building block is linked with the D-fucosamine building block through a 1,2-?-cis-glycosidic bond, the D-glucose building block is linked with the L-fucosamine building block through a 1,2-?-trans-glycosidic bond, and the construction of the 1,2-?-cis-glycosidic bond is conducted in a mixed solvent; and the mixed solvent includes two or more of dichloromethane, diethyl ether and thiophene.

Abstract: Disclosed is a composition for preventing or treating a degenerative brain disease. The composition includes, as an active ingredient, a MECP2 inhibitor for treating the degenerative brain disease, a polynucleotide encoding the MECP2 inhibitor or a recombinant virus containing the MECP2 inhibitor. The composition is useful for the treatment of a degenerative brain disease (particularly Alzheimer's syndrome) caused by beta-amyloid. In addition, the composition is effective in improving or ameliorating deterioration of cognitive functions and social deficits caused by Alzheimer's syndrome.

Abstract: The invention relates to medicine, particularly to agents for magnetic resonance diagnostics for oncological diseases. Developed for this purpose are a diagnostic preparation and a diagnostic method based on using said diagnostic preparation, in which a deuterated derivative of 3-O-methylglucose or a mixture of at least two different deuterated derivatives of 3-O-methylglucose is used as said preparation. The method according to the invention includes conducting magnetic resonance imaging and/or magnetic resonance spectroscopy on deuterium nuclei at a time after administration of the diagnostic preparation sufficient for the diagnostic preparation to accumulate in the tumor tissue of a subject in order to produce a magnetic resonance image and/or a magnetic resonance spectrum accordingly. The proposed method enables a highly informed diagnosis of oncological diseases.

Abstract: The present disclosure relates to a composition for preventing gray hair, promoting black hair and preventing, improving or treating vitiligo or hypochromatism, which contains fructose 1,6-bisphosphate or a salt, a solvate, a stereoisomer or a hydrate thereof as an active ingredient, and has been contrived to solve the problem of the prior art that appreciable effect cannot be achieved due to insignificant effect on melanin production. The composition of the present disclosure, which contains fructose 1,6-bisphosphate or a salt, a solvate, a stereoisomer or a hydrate thereof, provides superior effect of preventing gray hair, promoting black hair and treating vitiligo or hypochromatism.

Abstract: Provided are methods for treatment of neurodevelopmental disorders, such as Angelman Syndrome and autism comprising administering to an individual a composition comprising an agonist ligand of IGF-2 receptor. The agonist ligand of IGF-2 receptor may be IGF-2, or mannose-6-phosphate or a derivative thereof. Compositions comprising mannose-6-phosphate derivatives are also disclosed.

Abstract: System for generating a body degradation reduction program including a computing device configured to receive at least a degradation marker, retrieve a body degradation profile as a function of the at least a degradation marker, assign the body degradation profile to a degradation category, identify, using the degradation category and the body degradation profile, a plurality of lifestyle elements, wherein identifying the plurality of lifestyle elements includes calculating a plurality of lifestyle element amounts as a function of a respective effect of each of a plurality of lifestyle elements on the body degradation profile as a function of the degradation category, identifying the plurality of lifestyle elements as a function of the plurality of lifestyle element amounts, and generate a body degradation reduction program, using the plurality of lifestyle elements, wherein the body degradation reduction program includes a frequency and a magnitude of engagement of the plurality of lifestyle elements.

Abstract: The technology relates to a 3D printed hydrogel formed from a maleimide containing polymer cross-linked using a bis-thiol containing cross-linking agent having at least two thiol functional groups, processes for preparing the 3D printed hydrogel, and uses thereof.

Abstract: The invention discloses a treatment composition to treat nasal or oral dryness and allergy symptoms, and a method for using the same. Certain compositions include xylitol, at least two wetting agents, an aqueous carrier, and other active ingredients, such as a potassium salt, a sodium salt, and a preservative. The composition may be configured as a nasal or oral spray, and oral rinse, or a nasal gel.

Abstract: The present disclosure provides a set of spiked matrix standards comprising: one or more carriers, each carrier comprising: (a) a reference standard analyte in an amount that is different in each carrier; and (b) a blank matrix that is in admixture or in contact with the reference standard analyte. Methods for preparing and quantitating an analyte in a test sample comprises (a) providing one or more test samples to be tested for the presence of the analyte (b) providing a set of spiked matrix standards; (c) processing the standards and test samples and (d) quantitating the amount of analyte in each of the standards and test samples.

Abstract: Compositions and methods for treatment of mitochondrial respiratory chain dysfunction and other mitochondrial disorders are provided. Also disclosed are a number of screening assays having utility for the identification of agents which modulate the phenotype associated with mitochondrial respiratory chain dysfunction.

Abstract: The invention is directed to products and methods for preparing self-seeding vascular constructs generated as a bi-layered electrospun matrices, conjugated with EPC-specific antibodies and anti-thrombogenic agents on the inner surfaces of their lumens.

Abstract: The present invention is a cardioplegic solution that demonstrates better stability in pH, particulate matter formation and osmolality but at the same time demonstrates superior ability to preserve heart functions than currently available cardioplegic solutions. The cardioplegic solution comprises potassium (K+), magnesium (Mg2+), sodium (Na+), chloride (Cl?), gluconate, acetate, sulfate (SO42?), THAM and mannitol dissolved in water.

Abstract: The invention relates to a synthetic composition comprising human milk oligosaccharides for use in at least partially restoring the commensal gastrointestinal microbiota and preventing or mitigating antibiotic associated diarrhoea.

Abstract: In alternative embodiments, provided are solutions for peritoneal dialysis for use for maintaining or restoring the removal of small solutes and fluids in subjects with end-stage renal disease and/or congestive heart failure. In alternative embodiments, such solutions comprise carnitine, xylitol and at least one of glucose, glycerol and polydextrin.

Abstract: A method of treating or preventing a vaginal disease and/or a vaginal discomfort in a patient in need thereof, the method comprising administering a vaginal composition comprising isomaltulose to the vagina of the patient to restore and/or maintain Lactobacilli in the vagina, and/or to restore and/or maintain the vaginal acidity, wherein the content of the isomaltulose ranges from 0.05% (w/w) to 20.0% (w/w).

Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.

Abstract: Disclosed are a controlled-release dosage form with an absorption window in the upper gastrointestinal tract and a preparation method therefor, wherein the controlled-release dosage form comprises a controlled-release platform and a retention platform. The controlled-release platform is a pharmaceutical composition comprising a tablet core and a coating membrane; and the retention platform holds the controlled-release platform in the oral cavity. The operation steps of the controlled-release dosage form are as follows: placing the controlled-release platform in the retention platform, and fixing the retention platform on matching teeth in the oral cavity; taking out the controlled-release dosage form after 4-24 hours and replacing same with a new controlled-release platform; and re-fixing the retention platform on the matching teeth in the oral cavity to achieve the sustained and stable release of drugs.

Abstract: The present disclosure is directed to methods of treating patients with heart failure with reduced ejection fraction (HFrEF), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin. The methods disclosed herein can reduce the risk of a composite outcome of a first episode of worsening heart failure (hospitalization for heart failure or an urgent heart failure visit) or death from cardiovascular causes. Each of the three components of this composite outcome can also be reduced, as well as the total number of heart failure hospitalizations and deaths from cardiovascular causes. SGLT2 inhibitors, such as dapagliflozin, can also reduce a worsening of heart failure symptoms. The methods disclosed herein can also improve heart failure symptoms, health status, and quality of life.

Abstract: This disclosure relates generally to compositions and methods for preventing or treating mast cell mediated visceral pain.

Abstract: Provided herein is a method of improving the taste profile of a glucosylated terpene glycoside (GTG).

Abstract: The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and/or Syndrome X (metabolic syndrome) and/or loss of pancreatic beta cell function and/or wherein the remission of the metabolic disorder, preferably diabetic remission, is achieved and/or maintained.

Abstract: The application relates to a method for the prophylaxis or treatment of non-infectious diarrhea in a human, the method comprising administering to the human an effective amount of one or more human milk oligosaccharides.

Abstract: A method of preparing polylactic acid (PLA) microsphere and polylactic-co-glycolic acid (PLGA) microsphere is provided, including the following steps. A first solution is provided, including polylactic acid or polylactic-co-glycolic acid and an organic solvent. A second solution is provided, including polyvinyl alcohol, sodium carboxymethyl cellulose and an aqueous solution. The first solution is added to the second solution and, at the same time, the second solution is agitated until polylactic acid is solidified to form a plurality of polylactic acid microspheres, or until polylactic-co-glycolic acid is solidified to form a plurality of polylactic-co-glycolic acid microspheres. The polylactic acid microspheres or polylactic-co-glycolic acid microspheres are collected.

Abstract: Anti-microbial compositions for cleaning and sanitizing skin are disclosed. The anti-microbial compositions preferably comprises at least one quaternary ammonium chloride active and results in low irritation cleansing and sanitizing products that allow more frequent application.

Abstract: Glucosyl Stevia compositions are prepared from steviol glycosides of Stevia rebaudiana Bertoni. The glucosylation was performed by cyclodextrin glucanotransferase using the starch as source of glucose residues. The short-chain glucosyl Stevia compositions were purified to >95% content of total steviol glycosides. The compositions can be used as sweetness enhancers, flavor enhancers and sweeteners in foods, beverages, cosmetics and pharmaceuticals.

Abstract: A double network hydrogel including a polymer (A) having a persistence length between 10 and 1000 nm; a flexible polymer (B), wherein the persistence length is measured according to single molecule force microscopy measurement, wherein polymer (B) has an extended coil conformation at a first condition and a collapsed globular conformation at a second condition. Polymer (A) preferably is a polyisocyanate, while polymer (B) is a crosslinked flexible polymer like for example PNIPAM. A method for making a double network hydrogel.

Abstract: Sublingual Semaglutide compositions may comprise both Semaglutide or a salt thereof and a gastric peptide or salt thereof, in combination. The use of a gastric peptide mitigates gastrointestinal side effects of Semaglutide. A weight loss regimen comprises administration of sublingual Semaglutide compositions in the physical form of sublingual tablets. In preferred embodiments, each sublingual Semaglutide tablet provides about 500 mcg Semaglutide or 750 mcg Semaglutide in combination with 300 mcg of gastric peptide, with the gastric peptide preferably comprising Body Protection Compound-157 (BPC-157). Sublingual administration of Semaglutide finds use in suppressing appetite, losing weight, and maintaining a desired personal appearance.

Abstract: A system for ordered food preferences accompanying symptomatic inputs, the system including a computing device, the computing device designed and configured to retrieve a food profile pertaining to a user; select a first food element as a function of the food profile; select a second food element as a function of the first food element; create a food preference menu wherein the food preference menu contains the first food element and the second food element; and modify the food preference menu as a function of an entry contained within a symptomatic database.

Abstract: The application relates to a method for treating a patient with irritable bowel syndrome (IBS), the method comprising administering to the patient one or more neutral human milk oligosaccharides (HMOs) selected from 2?-fucosyllactose (2?-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I, lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), and combinations thereof.

Abstract: The present invention is directed to the use of one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof for the prophylaxis and/or treatment of one or more cardiac diseases in feline animals.

Abstract: Methods of enhancing homeostatic capacity in a subject are provided. Aspects of the methods include increasing the amplitude of an input resultant response of a homeostatic system component of the subject in a manner sufficient to enhance homeostatic capacity of the subject. Also provided are devices configured for use in practicing the methods. Aspects of the invention further include methods of treating a subject for a condition via enhancement of homeostatic capacity. The methods and devices described herein find use in a variety of applications.

Abstract: The present invention provides an agent or pharmaceutical composition for eliminating senescent cells, comprising an SGLT2 inhibitor.

Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.

Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.

Abstract: The disclosure relates to a pharmaceutical or dietary composition in the form of a soft gel capsule comprising a liquid or semisolid fill and a shell, the fill comprising at least one active ingredient or dietary supplement, dissolved, suspended or solubilized in a solution comprising water and alcohol, and a solubilizer and thickening agent. The disclosure furthermore relates to methods of reducing brittleness and fragility of such soft gel capsules.

Abstract: A method of performing cardiopulmonary resuscitation on a mammalian subject including the step of delivering an effective amount of a gliflozin solution during cardiac resuscitation through an intravenous or intraosseous route.